Interleukin-33 in health and disease

Nature Reviews Immunology

Volumn 16, Issue 11, 2016, Pages 676-689

  Liew, Foo Yew ^a,b   Girard, Jean Philippe ^c   Turnquist, Heth Roderick ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 33; RECEPTOR; ST2 PROTEIN; UNCLASSIFIED DRUG; CYTOKINE;

ALLERGIC DISEASE; BACTERIAL INFECTION; CENTRAL NERVOUS SYSTEM; EXTRACELLULAR SPACE; HELMINTHIASIS; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MOLECULAR BIOLOGY; MUSCULOSKELETAL DISEASE; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTOZOAL INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; TISSUE REPAIR; VIRUS INFECTION; ANIMAL; CHEMISTRY; DISEASE PREDISPOSITION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; METABOLISM; NEOPLASMS; REGENERATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CYTOKINES; DISEASE SUSCEPTIBILITY; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION; INTERLEUKIN-33; NEOPLASMS; ORGAN TRANSPLANTATION; REGENERATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84988385257     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2016.95     Document Type: Review

References (187)

1. Schmitz, J., et al. IL 33, an interleukin 1 like cytokine that signals via the IL 1 receptor-related protein ST2 and induces T helper type 2 associated cytokines. Immunity 23, 479-490 (2005
2. Xu, D., et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187, 787-794 (1998
3. Cayrol, C., & Girard, J. P. IL 33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31C, 31-37 (2014
4. Baekkevold, E. S., et al. Molecular characterization of NF HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79 (2003
5. Moffatt, M. F., et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363, 1211-1221 (2010
6. Torgerson, D. G., et al. Meta-Analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43, 887-892 (2011
7. Talabot-Ayer, D., et al. The mouse interleukin (Il)33 gene is expressed in a cell type-And stimulus-dependent manner from two alternative promoters. J. Leukoc. Biol. 91, 119-125 (2012
8. Lingel, A., et al. Structure of IL 33 and its interaction with the ST2 and IL 1RAcP receptors-insight into heterotrimeric IL 1 signaling complexes. Structure 17, 1398-1410 (2009
9. Liu, X., et al. Structural insights into the interaction of IL 33 with its receptors. Proc. Natl Acad. Sci. USA 110, 14918-14923 (2013
10. Carriere, V., et al. IL 33, the IL 1 like cytokine ligand for ST2 receptor, is a chromatin-Associated nuclear factor in vivo. Proc. Natl Acad. Sci. USA 104, 282-287 (2007
11. Roussel, L., Erard, M., Cayrol, C., & Girard, J. P. Molecular mimicry between IL 33 and KSHV for attachment to chromatin through the H2A H2B acidic pocket. EMBO Rep. 9, 1006-1012 (2008
12. Ali, S., et al. The dual function cytokine IL 33 interacts with the transcription factor NF?B to dampen NF?B-stimulated gene transcription. J. Immunol. 187, 1609-1616 (2011
13. Bessa, J., et al. Altered subcellular localization of IL 33 leads to non-resolving lethal inflammation. J. Autoimmun. 55, 33-41 (2014
14. Kearley, J., et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin 33 dependent response to infection. Immunity 42, 566-579 (2015
15. Bonilla, W. V., et al. The alarmin interleukin 33 drives protective antiviral CD8 T cell responses. Science 335, 984-989 (2012
16. Cayrol, C., & Girard, J. P. The IL 1 like cytokine IL 33 is inactivated after maturation by caspase 1. Proc. Natl Acad. Sci. USA 106, 9021-9026 (2009
17. Gadani, S. P., Walsh, J. T., Smirnov, I., Zheng, J., & Kipnis, J. The glia-derived alarmin IL 33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85, 703-709 (2015
18. Lefrancais, E., et al. IL 33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl Acad. Sci. USA 109, 1673-1678 (2012
19. Moussion, C., Ortega, N., & Girard, J P. The IL 1 like cytokine IL 33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel alarmin PLoS ONE 3, e3331 (2008
20. Luthi, A. U., et al. Suppression of interleukin 33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009
21. Talabot-Ayer, D., Lamacchia, C., Gabay, C., & Palmer, G. Interleukin 33 is biologically active independently of caspase 1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009
22. Kouzaki, H., Iijima, K., Kobayashi, T., O?Grady, S. M., & Kita, H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL 33 release and innate Th2 type responses. J. Immunol. 186, 4375-4387 (2011
23. Kamijo, S., et al. IL 33 mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J. Immunol. 190, 4489-4499 (2013
24. Cohen, E. S., et al. Oxidation of the alarmin IL 33 regulates ST2 dependent inflammation. Nat. Commun. 6, 8327 (2015
25. Haenuki, Y., et al. A critical role of IL 33 in experimental allergic rhinitis. J. Allergy Clin. Immunol. 130, 184-194 e111 (2012
26. Byers, D. E., et al. Long-term IL 33 producing epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest. 123, 3967-3982 (2013
27. Hudson, C. A., et al. Induction of IL 33 expression and activity in central nervous system glia. J. Leukoc. Biol. 84, 631-643 (2008
28. Chen, W. Y., Hong, J., Gannon, J., Kakkar, R., & Lee, R. T. Myocardial pressure overload induces systemic inflammation through endothelial cell IL 33. Proc. Natl Acad. Sci. USA 112, 7249-7254 (2015
29. Kakkar, R., Hei, H., Dobner, S., & Lee, R. T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287, 6941-6948 (2012
30. Rickard, J. A., et al. RIPK1 regulates RIPK3 MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157, 1175-1188 (2014
31. Pichery, M., et al. Endogenous IL 33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il 33 LacZ gene trap reporter strain. J. Immunol. 188, 3488-3495 (2012
32. Kuchler, A. M., et al. Nuclear interleukin 33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 173, 1229-1242 (2008
33. Xi, H., et al. IL 33 amplifies an innate immune response in the degenerating retina. J. Exp. Med. 213, 189-207 (2016
34. Molofsky, A. B., et al. Interleukin 33 and interferon-? counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43, 161-174 (2015
35. Carlock, C. I., et al. Unique temporal and spatial expression patterns of IL 33 in ovaries during ovulation and estrous cycle are associated with ovarian tissue homeostasis. J. Immunol. 193, 161-169 (2014
36. Sedhom, M. A., et al. Neutralisation of the interleukin 33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62, 1714-1723 (2013
37. Prefontaine, D., et al. Increased expression of IL 33 in severe asthma: evidence of expression by airway smooth muscle cells. J. Immunol. 183, 5094-5103 (2009
38. Hardman, C. S., Panova, V., & McKenzie, A. N. IL 33 citrine reporter mice reveal the temporal and spatial expression of IL 33 during allergic lung inflammation. Eur. J. Immunol. 43, 488-498 (2013
39. Reichenbach, D. K., et al. The IL 33/ST2 axis augments effector T cell responses during acute GVHD. Blood 125, 3183-3192 (2015
40. Savinko, T., et al. IL 33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 132, 1392-1400 (2012
41. Yasuda, K., et al. Contribution of IL 33 activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc. Natl Acad. Sci. USA 109, 3451-3456 (2012
42. Barlow, J. L., et al. IL 33 is more potent than IL 25 in provoking IL 13 producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 132, 933-941 (2013
43. Marvie, P., et al. Interleukin 33 overexpression is associated with liver fibrosis in mice and humans. J. Cell. Mol. Med. 14, 1726-1739 (2009
44. Masamune, A., et al. Nuclear expression of interleukin 33 in pancreatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G821-832 (2010
45. Manetti, M., et al. The IL1 like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann. Rheum. Dis. 69, 598-605 (2010
46. Sponheim, J., et al. Inflammatory bowel disease-Associated interleukin 33 is preferentially expressed in ulceration-Associated myofibroblasts. Am. J. Path 177, 2804-2815 (2010
47. Nakanishi, W., et al. IL 33, but not IL 25, is crucial for the development of house dust mite antigen-induced allergic rhinitis. PLoS ONE 8, e78099 (2013
48. Mager, L. F., et al. IL 33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Invest. 125, 2579-2591 (2015
49. Lefrancais, E., et al. Central domain of IL 33 is cleaved by mast cell proteases for potent activation of group 2 innate lymphoid cells. Proc. Natl Acad. Sci. USA 111, 15502-15507 (2014
50. Mohapatra, A., et al. Group 2 innate lymphoid cells utilize the IRF4 IL 9 module to coordinate epithelial cell maintenance of lung homeostasis. Mucosal Immunol. 9, 275-286 (2015
51. Kim, L. K., et al. AMCase is a crucial regulator of type 2 immune responses to inhaled house dust mites. Proc. Natl Acad. Sci. USA 112, E2891-E2899 (2015
52. Madouri, F., et al. Caspase 1 activation by NLRP3 inflammasome dampens IL 33 dependent house dust mite-induced allergic lung inflammation. J. Mol. Cell. Biol. 7, 351-365 (2015
53. Sanada, S., et al. IL 33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007
54. Bae, S., et al. Contradictory functions (activation/ termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin 33 biological activity. J. Biol. Chem. 287, 8205-8213 (2012
55. Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301-304 (1989
56. Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T., & Tominaga, S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 318, 83-87 (1993
57. Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P., & Busslinger, M. Alternative promoter usage of the Fos-responsive gene Fit 1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL 1 receptor. EMBO J. 13, 1176-1188 (1994
58. Lott, J. M., Sumpter, T. L., & Turnquist, H. R. New dog and new tricks: evolving roles for IL 33 in type 2 immunity. J. Leukoc. Biol. 97, 1037-1048 (2015
59. Molofsky, A. B., Savage, A. K., & Locksley, R. M. Interleukin 33 in tissue homeostasis, injury, and inflammation. Immunity 42, 1005-1019 (2015
60. Lohning, M., et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl Acad. Sci. USA 95, 6930-6935 (1998
61. Guo, L., et al. IL 1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc. Natl Acad. Sci. USA 106, 13463-13468 (2009
62. Turnquist, H. R., et al. IL 33 expands suppressive CD11b+ Gr 1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J. Immunol. 187, 4598-4610 (2011
63. Matta, B. M., et al. IL 33 is an unconventional Alarmin that stimulates IL 2 secretion by dendritic cells to selectively expand IL 33R/ST2+ regulatory T cells. J. Immunol. 193, 4010-4020 (2014
64. Matta, B. M., et al. Peri-AlloHCT IL 33 administration expands recipient T regulatory cells that protect mice against acute GVHD. Blood 128, 427-439 (2016
65. Vasanthakumar, A., et al. The transcriptional regulators IRF4, BATF and IL 33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat. Immunol. 16, 276-285 (2015
66. Kolodin, D., et al. Antigen-And cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell. Metab. 21, 543-557 (2015
67. Arpaia, N., et al. A distinct function of regulatory T cells in tissue protection. Cell 162, 1078-1089 (2015
68. Schiering, C., et al. The alarmin IL 33 promotes regulatory T cell function in the intestine. Nature 513, 564-568 (2014
69. Burzyn, D., et al. A special population of regulatory T cells potentiates muscle repair. Cell 155, 1282-1295 (2013
70. Zaiss, D. M., Gause, W. C., Osborne, L. C., & Artis, D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42, 216-226 (2015
71. Moro, K., et al. Innate production of T(H)2 cytokines by adipose tissue-Associated c Kit(+)Sca 1(+) lymphoid cells. Nature 463, 540-544 (2010
72. Neill, D. R., et al. Nuocytes represent a new innate effector leukocyte that mediates type 2 immunity. Nature 464, 1367-1370 (2010
73. Price, A. E., et al. Systemically dispersed innate IL 13 expressing cells in type 2 immunity. Proc. Natl Acad. Sci. USA 107, 11489-11494 (2010
74. Monticelli, L. A., et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045-1054 (2011
75. Hoyler, T., et al. The transcription factor GATA 3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37, 634-648 (2012
76. Mjosberg, J., et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37, 649-659 (2012
77. Yagi, R., et al. The transcription factor GATA3 is critical for the development of all IL 7R? expressing innate lymphoid cells. Immunity 40, 378-388 (2014
78. Spits, H., et al. Innate lymphoid cells-A proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013
79. Eberl, G., Di Santo, J. P., & Vivier, E. The brave new world of innate lymphoid cells. Nat. Immunol. 16, 1-5 (2015
80. Huang, Y., & Paul, W. E. Inflammatory group 2 innate lymphoid cells. Int. Immunol. 28, 23-28 (2016
81. Turnquist, H. R., et al. IL 1? driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J. Immunol. 181, 62-72 (2008
82. Rank, M. A., et al. IL 33 activated dendritic cells induce an atypical TH2 type response. J. Allergy Clin. Immunol. 123, 1047-1054 (2009
83. Turnquist, H. R., et al. mTOR and GSK 3 shape the CD4+ T cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 115, 4758-4769 (2010
84. Oshikawa, K., Yanagisawa, K., Tominaga, S., & Sugiyama, Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin. Exp. Allergy 32, 1520-1526 (2002
85. Besnard, A. G., et al. IL 33 activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 41, 1675-1686 (2011
86. Morita, H., et al. An interleukin 33 mast cell-interleukin 2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43, 175-186 (2015
87. Yang, Q., et al. IL 33 synergizes with TCR and IL 12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol. 41, 3351-3360 (2011
88. Gao, X., et al. Tumoral expression of IL 33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J. Immunol. 194, 438-445 (2015
89. Baumann, C., et al. T Bet-And STAT4 dependent IL 33 receptor expression directly promotes antiviral Th1 cell responses. Proc. Natl Acad. Sci. USA 112, 4056-4061 (2015
90. Smithgall, M. D., et al. IL 33 amplifies both Th1? and Th2 type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030 (2008
91. Bourgeois, E., et al. The pro Th2 cytokine IL 33 directly interacts with invariant NKT and NK cells to induce IFN-? production. Eur. J. Immunol. 39, 1046-1055 (2009
92. Kumar, S., Tzimas, M. N., Griswold, D. E., & Young, P. R. Expression of ST2, an interleukin 1 receptor homologue, is induced by proinflammatory stimuli. Biochem. Biophys. Res. Commun. 235, 474-478 (1997
93. Mildner, M., et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc. Res. 87, 769-777 (2010
94. Bulek, K., et al. The essential role of single Ig IL 1 receptor-related molecule/Toll IL 1R8 in regulation of Th2 immune response. J. Immunol. 182, 2601-2609 (2009
95. Zhao, J., et al. F Box protein FBXL19 mediated ubiquitination and degradation of the receptor for IL 33 limits pulmonary inflammation. Nat. Immunol. 13, 651-658 (2012
96. Buck, A. H., et al. Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. Nat. Commun. 5, 5488 (2014
97. Humphreys, N. E., Xu, D., Hepworth, M. R., Liew, F. Y., & Grencis, R. K. IL 33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180, 2443-2449 (2008
98. Hung, L. Y., et al. IL 33 drives biphasic IL 13 production for noncanonical Type 2 immunity against hookworms. Proc. Natl Acad. Sci. USA 110, 282-287 (2013
99. Wilson, S., et al. A late IL 33 response after exposure to Schistosoma haematobium antigen is associated with an up regulation of IL 13 in human eosinophils. Parasite Immunol. 35, 224-228
100. Hepworth, M. R., Maurer, M., & Hartmann, S. Regulation of type 2 immunity to helminths by mast cells. Gut Microbes 3, 476-481 (2012
101. Halim, T. Y., Krauss, R. H., Sun, A. C., & Takei, F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36, 451-463 (2012
102. Wilhelm, C., et al. An IL 9 fate reporter demonstrates the induction of an innate IL 9 response in lung inflammation. Nat. Immunol. 12, 1071-1077 (2011
103. Turner, J. E., et al. IL 9 mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J. Exp. Med. 210, 2951-2965 (2013
104. Van Dyken, S. J., et al. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and T cells. Immunity 40, 414-424 (2014
105. Salimi, M., et al. A role for IL 25 and IL 33 driven type 2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210, 2939-2950 (2013
106. Vannella, K. M., et al. Combinatorial targeting of TSLP, IL 25, and IL 33 in type 2 cytokine-driven inflammation and fibrosis. Sci. Transl. Med. 8, 337ra365 (2016
107. Howard, J. G., Hale, C., & Liew, F. Y. Immunological regulation of experimental cutaneous leishmaniasis. III. Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to Leishmania tropica. J. Exp. Med. 152, 594-607 (1980
108. Mosmann, T. R., & Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989
109. Kropf, P., Bickle, Q., Herath, S., Klemenz, R., & Muller, I. Organ-specific distribution of CD4+ T1/ST2+ Th2 cells in Leishmania major infection. Eur. J. Immunol. 32, 2450-2459 (2002
110. Rostan, O., et al. The IL 33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani. MBio 4, e00383-00313 2013
111. Gazzinelli, R. T., et al. Parasite-induced IL 12 stimulates early IFN-? synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153, 2533-2543 (1994
112. Coombes, J. L., & Hunter, C. A. Immunity to Toxoplasma gondii-into the 21st century. Parasite Immunol. 37, 105-107 (2015
113. Jones, L. A., et al. IL 33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur. J. Immunol. 40, 426-436 (2010
114. Ayimba, E., et al. Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. Clin. Exp. Immunol. 166, 218-226 (2011
115. Besnard, A. G., et al. IL 33 mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog. 11, e1004607 2015
116. Le, H. T., et al. IL 33 priming regulates multiple steps of the neutrophil-mediated anti-Candida albicans response by modulating TLR and dectin 1 signals. J. Immunol. 189, 287-295 (2012
117. Nelson, M. P., et al. IL 33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. J. Immunol. 186, 2372-2381 (2011
118. Piehler, D., et al. T1/ST2 promotes T helper 2 cell activation and polyfunctionality in bronchopulmonary mycosis. Mucosal Immunol. 6, 405-414 2013
119. Flaczyk, A., et al. IL 33 signaling regulates innate and adaptive immunity to Cryptococcus neoformans. J. Immunol. 191, 2503-2513 (2013
120. Brunner, M., et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 30, 1468-1473 (2004
121. Hoogerwerf, J. J., et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 36, 630-637 (2010
122. Alves-Filho, J. C., et al. Interleukin 33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16, 708-712 (2010
123. Li, C., et al. Interleukin 33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin. PLoS Pathog. 10, e1003918 2014
124. Malcolm, J., et al. IL 33 exacerbates periodontal disease through induction of RANKL. J. Dent. Res. 94, 968-975 (2015
125. Hazlett, L. D., et al. IL 33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 51, 1524-1532 (2010
126. Yin, H., et al. IL 33 promotes Staphylococcus aureus-infected wound healing in mice. Int. Immunopharmacol. 17, 432-438 (2013
127. Boomer, J. S., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594-2605 (2011
128. Otto, G. P., et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 2011
129. Hoogerwerf, J. J., et al. Loss of suppression of tumorigenicity 2 (ST2) gene reverses sepsis-induced inhibition of lung host defense in mice. Am. J. Respir. Crit. Care Med. 183, 932-940 (2011
130. Becerra, A., Warke, R. V., de Bosch, N., Rothman, A. L., & Bosch, I. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 41, 114-120 (2008
131. Miyagaki, T., et al. High levels of soluble ST2 and low levels of IL 33 in sera of patients with HIV infection. J. Invest. Dermatol. 131, 794-796 (2011
132. Walzl, G., et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1 driven immunopathology. J. Exp. Med. 193, 785-792 (2001
133. Aoki, R., et al. Mast cells play a key role in host defense against herpes simplex virus infection through TNF-Alpha and IL 6 production. J. Invest. Dermatol. 133, 2170-2179 (2013
134. Sesti-Costa, R., et al. The IL 33/ST2 pathway controls coxsackievirus B5 induced experimental pancreatitis. J. Immunol. 191, 283-292 (2013
135. Chang, Y. J., et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12, 631-638 (2011
136. Kayamuro, H., et al. Interleukin 1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J. Virol. 84, 12703-12712 (2010
137. Kurowska-Stolarska, M., et al. IL 33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6477 (2009
138. Sakashita, M., et al. Association of serum interleukin 33 level and the interleukin 33 genetic variant with Japanese cedar pollinosis. Clin. Exp. Allergy 38, 1875-1881 (2008
139. Bartemes, K. R., et al. IL 33 responsive lineage CD25+CD44hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J. Immunol. 188, 1503-1513 (2012
140. Stolarski, B., Kurowska-Stolarska, M., Kewin, P., Xu, D., & Liew, F. Y. IL 33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 185, 3472-3480 (2010
141. Imai, Y., et al. Skin-specific expression of IL 33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl Acad. Sci. USA 110, 13921-13926 (2013
142. Shimpo, M., et al. Serum levels of the interleukin 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004
143. Miller, A. M., et al. IL 33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346 (2008
144. Han, G. W., et al. Serum levels of IL 33 is increased in patients with ankylosing spondylitis. Clin. Rheumatol 30, 1583-1588 (2011
145. Tang, S., et al. Increased IL 33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis. Clin. Dev. Immunol. 2013, 985301 (2013
146. Li, C., et al. Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res. Ther. 16, R105 2014
147. Leung, B. P., Xu, D., Culshaw, S., McInnes, I. B., & Liew, F. Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173, 145-150 2004
148. Xu, D., et al. IL 33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl Acad. Sci. USA 105, 10913-10918 (2008
149. Palmer, G., et al. Inhibition of interleukin 33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749 (2009
150. Komai-Koma, M., et al. IL 33 activates B1 cells and exacerbates contact sensitivity. J. Immunol. 186, 2584-2591 (2011
151. Millar, N. L., et al. MicroRNA29a regulates IL 33 mediated tissue remodelling in tendon disease. Nat. Commun. 6, 6774 (2015
152. Kuswanto, W., et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin 33 dependent accumulation of regulatory T cells. Immunity 44, 355-367 (2016
153. Pastorelli, L., et al. Epithelial-derived IL 33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl Acad. Sci. USA 107, 8017-8022 (2010
154. Oboki, K., et al. IL 33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581-18586 (2010
155. Duan, L., et al. Interleukin 33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T cell responses in mice. Mol. Med. 18, 753-761 (2012
156. Monticelli, L. A., et al. IL 33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc. Natl Acad. Sci. USA 112, 10762-10767 (2015
157. Axelsson, L. G., Landstrom, E., Goldschmidt, T. J., Gronberg, A., & Bylund-Fellenius, A. C. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic and NK cell depleted SCID mice. Inflamm. Res. 45, 181-191 (1996
158. Miller, A. M., et al. Interleukin 33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 107, 650-658 (2010
159. Hasan, A., et al. IL 33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol. 15, 19 (2014
160. Brestoff, J. R., et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242-246 (2015
161. Lee, M. W., et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 160, 74-87 (2015
162. Barbour, M., et al. IL 33 attenuates the development of experimental autoimmune uveitis. Eur. J. Immunol. 44, 3320-3329 (2014
163. Maywald, R. L., et al. IL 33 activates tumor stroma to promote intestinal polyposis. Proc. Natl Acad. Sci. USA 112, E2487-2496 (2015
164. Levescot, A., et al. BCR-ABL-induced deregulation of the IL 33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res. 74, 2669-2676 (2014
165. Brunner, S. M., et al. Interleukin 33 prolongs allograft survival during chronic cardiac rejection. Transpl. Int. 24, 1027-1039 (2011
166. McDonald-Hyman, C., Turka, L. A., & Blazar, B. R. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci. Transl. Med. 7, 280rv282 (2015
167. Mathews, L. R., et al. Elevated ST2 distinguishes incidences of pediatric heart and small bowel transplant rejection. Am. J. Transplant. 16, 938-950 (2016
168. Vander Lugt, M. T., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N. Engl. J. Med. 369, 529-539 (2013
169. Zhang, J., et al. ST2 blockade reduces sST2 producing T cells while maintaining protective mST2 expressing T cells during graft-versus-host disease. Sci. Transl. Med. 7, 308ra160 (2015
170. Ponce, D. M., et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood 125, 199-205 (2015
171. Pascual-Figal, D. A., et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann. Thorac Surg. 92, 2118-2124 (2011
172. Villalta, S. A., et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 6, 258ra142 (2014
173. Rak, G. D., et al. IL 33 dependent group 2 innate lymphoid cells promote cutaneous wound healing. J. Invest. Dermatol. 136, 487-496 (2016
174. Luzina, I. G., et al. Interleukin 33 potentiates bleomycin-induced lung injury. Am. J. Respir. Cell. Mol. Biol. 49, 999-1008 (2013
175. Li, D., et al. IL 33 promotes ST2 dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J. Allergy Clin. Immunol. 134, 1422-1432 e1411 (2014
176. McHedlidze, T., et al. Interleukin 33 dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357-371 (2013
177. Li, J., et al. Biliary repair and carcinogenesis are mediated by IL 33 dependent cholangiocyte proliferation. J. Clin. Invest. 124, 3241-3251 (2014
178. Lee, J. S., Seppanen, E., Patel, J., Rodero, M. P., & Khosrotehrani, K. ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis. Exp. Dermatol. 25, 71-74 (2016
179. Yasuoka, S., et al. Production and functions of IL 33 in the central nervous system. Brain Res. 1385, 8-17 (2011
180. Jiang, H. R., et al. IL 33 attenuates EAE by suppressing IL 17 and IFN-gamma production and inducing alternatively activated macrophages. Eur. J. Immunol. 42, 1804-1814 (2012
181. Luo, Y., et al. Interleukin 33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain Res. 1597, 86-94 (2015
182. Pomeshchik, Y., et al. Interleukin 33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav. Immun. 44, 68-81 (2015
183. Fu, A. K., et al. IL 33 ameliorates Alzheimer?s disease-like pathology and cognitive decline. Proc. Natl Acad. Sci. USA 113, E2705-2713 (2016
184. Chapuis, J., et al. Transcriptomic and genetic studies identify IL 33 as a candidate gene for Alzheimer?s disease. Mol. Psychiatry 14, 1004-1016 (2009
185. Yu, J. T., et al. Implication of IL 33 gene polymorphism in Chinese patients with Alzheimer?s disease. Neurobiol. Aging 33, 1014 e1011 1014 (2012
186. Brint, E. K., et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5, 373-379 (2004
187. Martin, P., et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL 33 deficiency. Arthritis Res. Ther. 15, R13 (2013